Antimicrobial Agents and Intestinal Microflora

Size: px
Start display at page:

Download "Antimicrobial Agents and Intestinal Microflora"

Transcription

1 Bifidobacteria Micrlora Vol. 1(1), 25-37, 1982 Antimicrobial Agents and Intestinal Micrlora Rintaro NAKAYA, Toshio CHIDA, and Harumi SHIBAOKA Department Microbiology, Tokyo Medical and Dental University School Medicine, Yushima, Bunkyo-ku, Tokyo 113 (Received 15 October, 1981) The results studies described in this communication indicate that antimicrobials cause suppression normal aerobic and anaerobic flora in a variety ways. In conclusion, it is summarized that: (i) Changes in intestinal micrlora are reflection antibacterial spectrum and activity specific to antibiotic administered. (ii) Degrees alteration in flora correlate well to concentrations drug in intestinal contents, and particularly, with antibiotics parenteral administration, y depend on concentrations excreted in bile. (iii) Changes in flora take place within 24 hr drug administration, and at least 2 weeks and usually 3 to 4 weeks are required for recovery flora to normal levels. (iv) When bacteria that harbor R plasmids mediating resistance to antibiotic used exist in flora, drug is inactivated, resulting in selective overgrowth organisms. After withdrawal drug organisms may disappear or decrease in number. (v) Bifidobacteria are generally very sensitive to most antibiotics tested. (vi) Overgrowth yeasts is seen during course drug administration. (vii) No adverse consequences ascribable to direct effects changes in flora are observed. Key words: Antimicrobial agents; intestinal flora; cephalosporins; penicillins; pipemidic acid; DJ-6783; Panfuran S; clioquinol It is my great honor and privilege, as first speaker in this Symposium, to present studies myself and my colleagues. In this paper we will discuss studies on mode changes in intestinal micrlora man and experimental animals upon administration a variety antimicrobial agents in particular, citing studies carried out during recent years in our laboratories. Many reports have been made on disturbances in normal distribution and balance intestinal bacteria after oral or parenteral administration antimicrobial agents used for systemic infection rapy. In earlier studies, only coliform bacteria were used as indicator organisms to follow up such disturbances in flora. It has, however, become a recent trend to study alteration in both aerobic and anaerobic bacteria (2, 6-9). A variety aims are possible for studies on alteration intestinal flora resulting from administration antimicrobial agents. (i) Determination quantitative and qualitative changes in bacterial groups flora. (ii) Determination period time alteration and recovery flora to normal. (iii) Investigation emergence and colonization antibiotic- bacteria. (iv) Investigation adverse reactions host due to alteration in flora. (v) Determination effects on metabolism bile acids and absorp-

2 26 R. NAKAYA et al. Table 1. Subjects, routes, and dosages for administration agents studied antimicrobial tion substances produced in colon. (vi) Determination effects on host's mechanisms defense against infection. The purpose this report is to present a summarized review our studies on effects antimicrobial agents on aerobic and anaerobic flora in human and animal feces as listed in Table 1. The experimental methods used in se studies are those exclusively established by Mitsuoka et al. (4). 1. Cephalosporins Cefazolin (CEZ): Two beagle dogs were intravenously injected with 200 mg CEZ per kg body weight per day for 30 days (CEZ-200 group). Two dogs that were not given drug served as controls. Stool specimens from se animals were analysed for both aerobic and anaerobic bacteria. The effects CEZ treatment on total flora and individual bacterial groups are shown in Fig. 1. A 2.5-fold decrease in total flora was observed in CEZ-200 group compared with control group. This modest difference is accounted for by elimination Eubacteria and Peptococcaceae and dramatic suppression Bacteroides, Bifidobacteria and Lactobacilli Fig. 1. Effect cefazolin on fecal micrlora beagle dogs after intravenous injections 200 mg/kg/day for 1 month. in CEZ-200 group. In contrast, Streptococci showed a 5-fold increase, while Enterobacteriaceae decreased 16-fold. When total flora is divided into aerobes and anaerobes, significant difference seen was a decrease in total anaerobic organisms in CEZ-200 group. With respect to detection frequency, re was a consistent tendency for loss anaerobic bacteria in CEZ-200 group. Cefazolin and cefoxitin (CFX): Twelve

3 ANTIMICROBIAL AGENTS AND INTESTINAL MICROFLORA beagle dogs were divided equally into 4 groups. One group received no antibiotic agent, anor group received 80 mg CEZ per kg per day (CEX-80 group), and third and fourth groups were given 80 and 400 mg CFX per kg per day, respectively (CFX-80 and CFX-400 groups). The drugs were intravenously injected into animals for 14 days. The effects CEZ and CFX on intestinal flora were observed by examination stool specimens obtained on day before treatment had begun (day 0 study), on days 2, 8, and 15 study during treatment period, and on days 22, 29, 36, and 43 study in period drugs were withdrawn. Figure 2 shows time sequence changes in mean log counts total flora and each bacterial group in CEZ-80 group. (R. Nakaya, T. Chida, H. Shibaoka, N. Okamura, S. Horiuchi, N. Goto, T. Inoue, H. Une, Y. Osada and H. Ogawa, Jpn. J. Bacteriol. 35 : 321, 1980). Most aerobes ( right-hand panel Fig. 2) and anaerobes ( left-hand panel Fig. 2) were strikingly decreased or eliminated one day after administration began (day 2 study), except for Streptococci which were reduced only slightly in number (1/16 count on day 0 study). The suppression flora was seen to continue during treatment period, although a sign recovery flora to normal was observed at end treatment (day 15 study). In particular, bacteria belonging to Enterobacteriaceae group increased to level existing prior to treatment. After withdrawal CEZ, counts most bacterial groups gradually increased to normal within 3 weeks and almost complete recovery was seen 4 weeks after end drug administration. Similar alterations in fecal flora were observed in CFX-80 and CFX-400 groups. Time sequence changes in mean log counts flora in CFX-400 group are shown in Fig. 3. On day 2 study all anaerobes were eliminated, while Streptococci showed a 126-fold de- Fig. 2. Effect cefazolin on fecal micrlora beagle dogs. Intravenous injections 80 mg/ kg/day for 14 days.

4 Fig. 3. Effect cefoxitin on fecal micrlora beagle dogs. Intravenous injections 400 mg/ kg/day for 14 days. crease which represented total flora. Bacteria belonging to Enterobacteriace and Lactobacillus groups, and yeasts as well as Streptococci tended to increase during treatment period, whereas or bacterial groups were suppressed until a week after withdrawal CFX. The amounts CEZ and CFX excreted into bile beagle dogs were monitored (data not shown). By 8 hr after intravenous injection, 4.1 % CEZ was recovered in CEZ-80 group, whereas 1.0% CFX was recovered in CFX-400 group. These results well account for suppression flora in stool specimens obtained one day after drug administration. The degrees suppression flora observed in two groups were almost identical. It is indicated that this is due to presence comparable concentrations both drugs in intestinal contents animals used. SM-1652, a new cephalosporin: The subjects studied were healthy adult male human volunteers (subjects No. 16, 17, and 18). Fecal specimens were collected prior to administration drug (day 0 study) and on days 2, 4, and 7 study into treatment period, and at 1 and 2 weeks after end treatment. All three subjects received intravenously a single dose 1 g SM-1652 (Sumitomo Chemical Co., Osaka, and Yamanouchi Pharmaceutical Co., Tokyo) per day for 6 days. Stool specimens were analysed for aerobic and anaerobic bacteria. Fecal levels drug were also determined for all three subjects during treatment period (R. Nakaya, T. Chida, H. Shibaoka, and H. Sagara, Jpn. J. Bacteriol. 36: 370, 1981; Manuscripts submitted to Chemorapy). SM-1652 caused drastic suppression normal aerobic and anaerobic flora in subjects No. 16 and 17 on days 3 and 2 study after administration drug, respectively, and most organisms were eliminated within treatment period. Typical changes observed in subject No. 17 are shown in ' upper panels Fig. 4. The changes in flora in subject No. 17 were similar to, but more striking than, those in beagle dogs treated with CEZ and CFX

5 ANTIMICROBIAL AGENTS AND INTESTINAL MICROFLORA Fig. 4. Effect SM-1652 on fecal micrlora volunteer No. 17 and concentrations d rug in fecal specimens. as mentioned previously. All bacteria, in intestinal flora were strongly suppressed on day 2 study (one day after first injection SM-1652), and n eliminated over administration period until 1 week after withdrawal drug. It is noteworthy that only yeasts showed overgrowth during administration period, and accounted for total counts flora. Overgrowth yeasts was also recognized in or two subjects. The significant difference was drastic suppression Streptococci and Enterobacteriaceae in subject No. 17 throughout administration period compared with results seen in beagle dogs treated with CEZ and CFX. It is suggested that such a difference is accounted for by antibacterial spectrum specific for each drug as well as by concentration drug in intestinal contents. In lower panels Fig. 4 are shown drug concentrations in stool specimens obtained on days 2, 4, and 7 study. Approximately 30% drug injected was recovered from stools, which corresponded to an average concentration 1,200ƒÊg active form SM-1652 per g stool. It is very likely that high concentrations drug in intestinal contents strongly affected becterial composition stools. Subject No. 18 showed a quite distinct course changes in flora as shown in Fig. 5, and refore more detailed studies were carried out. The total counts organisms remained more or less unchanged throughout experimental period. Organisms Bacteroidaceae increased in number on day 4 study by more than ten times that on day 0 study, and overgrowth remained throughout administration period and until 7 days after

6 R. NAKAYA et al. Fig. 5. Effect SM-1652 on fecal micrlora volunteer No. 18 and concentrations drug in fecal specimens. withdrawal SM During this period Bacteroidaceae represented total flora count ( upper left panel Fig. 5). Or anaerobes were all eliminated except for lecithinase-negative Clostridia which showed an increase in number. Among aerobic bacterial groups, Enterobacteriaceae showed a 100-fold increase on day 4 study as compared to figure for pretreatment, though numbers were reduced to normal levels on day 14 study ( upper right panel Fig. 5). Streptococci and Lactobacilli were slightly suppressed but not to extent as in subjects No. 16 and 17. An increase in numbers approximately 2.5 log cycles was observed for yeasts on day 7 study. The SM-1652 concentrations in stool specimens are shown in lower panels Fig. 5, indicating that y were below detection limit assay active form drug (=2ƒÊg/g) on days 2, 4, and 7 study. The failure in detection drug in fecal samples subject No. 18 prompted us to search for presence any organisms that inactivate drug among predominant bacterial groups flora. Individual isolates were tested for susceptibility to SM-1652 in vitro. As a result, it was found that predominant species in Enterobacteriaceae was Escherichia coli, which was multiply to a variety antibiotics including SM-1652 and produced ƒà-lactam.ase. The strains E. coli isolated on days 0, 2, 4, 7, and 14 study showed an identical resistance pattern and harbored a conjugative R plasmid mediating multiple antibiotic resistance to SM-1652 and or ƒà-lactam antibiotics, streptomycin and tetracycline. Some strains Bacteroidaceae tested for resistance were also found to be to SM-1652 and produce ƒà-lactamase, and were identified as

7 ANTIMICROBIAL Fig. 6. Presence isms aceae 18. Bacteroidaceae in fecal Bacter, SM-1652 micrlora (total lactamase ganisms Enterobacteriaceae E. spectively. coli tended coli disappeared to by in 18 drug-inactivating No. 18 are organ- E. fecal be speci- accounted activity se findings as on follows Veillonellae Staphylococci Bacilli Meg asphaera Curved rods Failure summarized Streptococii Entrobacteriaceae C. perfringens Clostridia-or bacterial study. above Bifidobacteria Peptococcaceae Lactobacilli pre- withdrawal can The exbegan Total Bacteroidaceae Eubacteria total re- most The 21 drug No. organisms. subject decrease. subject in during among day or- injection after on pres- organisms drug proportions detection mens B. vulgatus Bacteroidaceae, becoming However, pronouncedly species isms in and and before period, SM-1652, flora increased groups. Entero- Entero-R, 6 shows These dominant for Figure proportions treatment ; SM-1652 vulgatus. and and Entero, re- coli. Bacteroides in ; SM-1652 number) positive, Escherichia isted vulgatus; (total No. number) MICROFLORA : Yeasts Molds G(-)rod anaerobe: G(-)rod aerobes Total aerobes Total anaerobes (i) Ĉ-lactamase-producing vulgatus intestinal (ii) had been coli inhabitants micrlora administration These E. and subject B. before SM organisms almost 31 pletely inactivated SM-1652 excreted into intestinal tract during treatment and showed a selective overgrowth in flora and comprised most predominant bacterial group during administration period. Two groups cynomolgus monkeys, five in each group, were used to observe effect SM-1652 on intestinal flora. One group received intravenous injections 600 mg per kg body weight per day for 24 weeks. Stool specimens from se animals were tested for aerobic and anaerobic bacteria at 12th and 24th week administration period. The or group not given drug served as a control. As shown in Fig. 7, a pronounced suppression anaerobic flora was recognized in experimental groups, particularly 12 weeks into treatment period, as compared to control group. In contrast, Enterobacteriaceae and yeasts showed a significant increase, while Lactobacilli and Streptococci remained unchanged. organ- volunteer positive, Bacteroides AND INTESTINAL Enterobacteri- Bacteroidaceae bacteriaceae ence and Bacter-R, Ĉ-lactamase sistant AGENTS com- Fig. 7. Effect SM-1652 on fecal micrlora cynomolgus monkeys after intravenous injections 600 mg/kg/day for 12 and 24 weeks.

8 R. NAKAYA et al. Fig. 8. Effect cefoperazone on fecal micrlora volunteer A and concentrations drug in fecal specimens. Cefoperazone (CPZ): CPZ is one cephalosporin antibiotics that exhibits a potent activity to Pseudomonas aeruginosa and Gram-negative enteric bacteria (3). A study design similar to that an SM-1652 study was used to reveal effect CPZ on human and beagle dog intestinal flora (Manuscripts in preparation). Three adult male volunteers (subjects A, B, and C) were given intravenous injections 1 g CPZ, 2 times daily, for 5.5 days. The changes in flora se subjects were essentially similar to those described for subjects No. 16 and 17 treated with SM Figure 8 depicts data subject A as a representative example. The fecal CPZ concentrations at 1 and 5 days after starting drug administration reached 2 and 3.5 mg per gram stool, respectively, as presumed by its excretion in bile (5). The aerobic and anaerobic bacteria were eliminated to below detection level, while only yeasts showed an overgrowth. Recovery flora to normal levels was seen at 13 days after cessation CPZ administration. The effects CPZ on fecal flora were also investigated in beagle dogs by intra- Total Bacteroidaceae Eubacteria Bifidobacteria Peptococcaceae Lactobacilli Streptococci Enterobacteriaceai Clostridia Veillonellae Staphylococci Corynebacteria Bacilli Yeasts Total Total aerobes anaerobes Fig. 9. Effect cefoperazone on fecal micrlora beagle dogs after intravenous injections 100, 200, and 400 mg/kg/day for 1 month. venous as well as intramuscular injections. In Fig. 9 are shown data experiments on intravenous injection. A total 10 beagle dogs were assigned to 4 groups, each consisting 2 or 3 animals: 3 groups were given intravenous injections 100, 200, and

9 ANTIMICROBIAL AGENTS AND INTESTINAL MICROFLORA 400 mg CPZ per kg body weight per day for 1 month, respectively; remaining group served as a control. It was evident that anaerobic bacteria and Lactobacilli were suppressed, but Streptococci and Enterobacteriaceae remained unchanged. 2. Penicillins Piperacillin (PIPC) and ampicillin (ABPC). Table 2 shows effects PIPC (10) and ABPC on intestinal micrlora beagle dogs (6). Two groups animals were treated by intravenous injection 250 mg and 1 g PIPC per kg body weight per day (T-250 mg/kg and T-1 g/kg groups, respectively) for 1 month, and one group with 1 g ABPC (ABPC-1 g/kg group) in a similar manner. PIPC strongly suppressed Bifidobacteria, Clostridia, and Streptococci, and slightly, Bacteroidaceae, Peptococcaceae, Lactobacilli, and Streptococci. ABPC showed more or less similar effects to those PIPC. Susceptibilities anaerobic bacteria to PIPC ABPC, and some Ĉ-lactam. antibiotics were determined in vitro (Table 3) (1). The changes in anaerobic flora seen in, beagle dogs seem to be a reflection susceptibilities organisms in vitro in intestinal flora. Rabbits (New Zealand White) were used to test effects PIPC and ABPC on intestinal flora (R. Nakaya, T. Chida, S. Horiuchi, N. Okamura, H. Taniguchi, N. Goto, and K. Fujimoto, Jpn. J. Bacteriol. 33: 262, 1978). The animals (3 in each group) were intravenously injected with 50 and 500 mg each antibiotic per kg body weight per day for 15 days. Both drugs significantly suppressed anaerobic flora but not aerobic bacteria. In se experiments, it was observed that rabbits experimental groups lost body weight and died diarrhea. It is known that penicillins exhibit effects toxic to rabbits and guinea pigs. This was also confirmed in this study. 3. Pipemidic Acid and DJ-6783 Pipemidic acid (PPA; Dainippon Pharmaceutical Co., Osaka) and DJ-6783 (sodium 5-ethyl-5, 8-dihydro-8-oxuro[3, 2-b] [1, 8]naphthyridine-7-carboxylate monoacetate; Daiichi Seiyaku Co., Tokyo) are chemically synsized, oral antibac- Table 2. Effects piperacillin and ampicillin on intestinal micrlora beagle dogs (6)

10 R. NAKAYA et al. Table 3. Susceptibility in vitro anaerobic organisms against piperacillin and or Ĉ-lactam antibiotics (1) terial drugs related to nalidixic acid. The vitro and were quite distinct from those drugs have an antibacterial activity specific caused by various 13-lactam. antibiotics described to bacteria belonging to Enterobacteriaceae above. group in intestinal flora. When 20 mg PPA and DJ-6783 per kg body weight 4. Panfuran S were administered orally twice a day to beagle dogs for 7 days (3 in each group), Enterobacteriaceae organisms were significantly Panfuran S (PFS, dihydroxym.ethylfuratrizine, Toyama Chemical Co., Tokyo) is a reduced and eliminated, respectively syntic antibacterial drug which has a (Figs. 10 and 11) (Manuscripts in preparation). broad spectrum. PFS treatment was per- Or changes observed were formed on 11 adult patients with diseases decrease Eubacteria and increase urinary tract who were required to be yeasts in both experimental groups treated with chemorapeutic agents prior animals. It is indicated that effects to or after surgical operations. A dose se drugs on flora were well in agreement with ir antibacterial spectrum in eir 250 or 500 mg, 4 times a day, was administered to subjects for 3 days (R.

11 ANTIMICROBIAL AGENTS AND INTESTINAL MICROFLORA Fig. 10. Effect pipemidic acid on fecal micrlora beagle dogs and concentrations drug in fecal specimens. Oral administration 20 mg/kg, twice a day, for 7 days. Fig. 11. Effect DJ-6783 on fecal micrlora beagle dogs and concentrations drug in fecal specimens. Oral administration 20 mg/kg, twice a day, for 7 days.

12 R. NAKAYA et al. Fig. 12. Effect Panfuran S on fecal micrlora patients. Oral administration eir 250 or 500 mg, 4 times a day, for 3 days. Pre-tr, pretreatment; post-tr, posttreatment. Nakaya, Y. Terawaki, and H. Inugami, Jpn. J. Bacteriol. 30 : 113, 1975). As shown in Fig. 12, significant alterations in intestinal flora were observed after treatment. Most bacterial groups were decreased in number and detection frequency, particularly Clostridia and Eubacteria showing a pronounced decrease. Enterobacteriaceae and Streptococci remained unchanged, while Corynebacteria increased in detection frequency. 5. Clioquinol We have previously reported that patients suffering from subacute myelo-optic neuropathy (SMON) show marked abnormalities in fecal flora, presumably due to administration clioquinols (Cli) (7). Cli are syntic antibacterial drugs that have been widely used for treatment and prophylaxis mild gastrointestinal disorders, but it is now established that se drugs cause SMON. Table 4 shows results our investigations on fecal flora SMON patients as compared to those normal subjects (7), indicating remarkable alterations in flora SMON patients. References (1) Chida, T., K. Ishizu, K. Fukuda, and R. Nakaya Susceptibility anaerobic bacteria to a new semisyntic penicillin T-1220 and related drugs. Igaku-no-Ayumi 101: (2) Finegold, S.M Anaerobic bacteria in human diseases. Academic Press, New York. (3) Matsubara, N., S. Minami, T. Muraoka, I. Saikawa, and S. Mitsuhashi In vitro antibacterial activity cefoperazone (T-1551), a new semisyntic cephalosporin. Antimicrob. Agents Chemor. 16: (4) Mitsuoka, T., K. Ohno, Y. Benno, K. Suzuki, and K. Namba Die Faekalflora bei Menschen. IV. Mitteilung: Vergleich des neu entwickelten Verfahrens mit dem bisherigen blichen Verfahren zur Darmfloraanalyse. u Zbl. Bakt. Hyg., I. Abt. Orig. A 234: (5) Nakamura, T., I. Hashimoto, Y. Sawada, J. Mikami, E. Bekki, S. Hirasawa, H. Abe, and Y. Watanabe Cefoperazone concentration in bile and gall bladder wall after intravenous administration. Antimicrob. Agents Chemor. 18: (6) Nakaya, R., T. Chida, K. Ishizu, and H. Taniguchi Effects a new semisyntic

13 ANTIMICROBIAL AGENTS AND INTESTINAL MICROFLORA Table 4. Fecal flora in normal subjects and SMON patientsa(7) penicillin T-1220 on intestinal micrlora in dogs. Igaku-no-Ayumi 101: (7) Nakaya, R., H. Inugami, T. Mitsuoka, and A. Igata Abnormalities in fecal flora subacute myelo-optic neuropathy (SMON) patients and effects clioquinols on human intestinal flora, p In J.D. Williams, and A.M. Geddes (ed.) Chemorapy, Vol. 4. Plenum Publishing Corporation, New York. (8) Nanri, S Relationship between intestinal flora and urinary tract infection. J. Japan. Assoc. Infect. Dis. 54: (9) Sutter, U.L., and S.M. Finegold The effect antimicrobial agents on human faecal flora: studies with cephalexin, cyclacillin and clindamycin, p In F.A. Skinner, and J.C. Carr (ed.), The normal microbial flora man. Academic Press, Inc., London. (10) Ueo, K., Y. Fukuoka, T. Hayashi, T. Yasuda, H. Taki, M. Tai, Y. Watanabe, I. Saikawa, and S. Mitsuhashi In vitro and in vivo antibacterial activity T-1220, a new semisyntic penicillin. Antimicrob. Agents Chemor. 12:

ECOLOGICAL IMPACT OF NARROW SPECTRUM ANTIMICROBIAL AGENTS COMPARED TO BROAD SPECTRUM AGENTS ON THE HUMAN INTESTINAL MICROFLORA CARL ERIK NORD

ECOLOGICAL IMPACT OF NARROW SPECTRUM ANTIMICROBIAL AGENTS COMPARED TO BROAD SPECTRUM AGENTS ON THE HUMAN INTESTINAL MICROFLORA CARL ERIK NORD Old Herborn University Seminar Monograph 3: Consequences of antimicrobial therapy for the composition of the microflora of the digestive tract. Editors: Carl Erik Nord, Peter J. Heidt, Volker Rusch, and

More information

USA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION

USA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION VIRBAC CORPORATION USA Product Label http://www.vetdepot.com P.O. BOX 162059, FORT WORTH, TX, 76161 Telephone: 817-831-5030 Order Desk: 800-338-3659 Fax: 817-831-8327 Website: www.virbacvet.com CLINTABS

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amfipen LA 100 mg/ml suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Each ml contains:

More information

Part II SUMMARY OF PRODUCT CHARACTERISTICS. Each tablet contains 25 mg Clindamycin (as Clindamycin Hydrochloride)

Part II SUMMARY OF PRODUCT CHARACTERISTICS. Each tablet contains 25 mg Clindamycin (as Clindamycin Hydrochloride) Clindacyl 25mg Tablets Vm 08007/4104 Part II SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CLINDACYL 25 MG TABLETS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet

More information

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria

More information

Microbiology ( Bacteriology) sheet # 7

Microbiology ( Bacteriology) sheet # 7 Microbiology ( Bacteriology) sheet # 7 Revision of last lecture : Each type of antimicrobial drug normally targets a specific structure or component of the bacterial cell eg:( cell wall, cell membrane,

More information

4.5. Special precautions for use Special precautions to be taken by person administering the veterinary medicinal product to animals

4.5. Special precautions for use Special precautions to be taken by person administering the veterinary medicinal product to animals 1.B1. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT AMOXYCOL Soluble Powder 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances: Amoxicillin trihydrate 640.0

More information

USA Product Label LINCOCIN. brand of lincomycin hydrochloride tablets. brand of lincomycin hydrochloride injection, USP. For Use in Animals Only

USA Product Label LINCOCIN. brand of lincomycin hydrochloride tablets. brand of lincomycin hydrochloride injection, USP. For Use in Animals Only USA Product Label http://www.vetdepot.com PHARMACIA & UPJOHN COMPANY Division of Pfizer Inc. Distributed by PFIZER INC. 235 E. 42ND ST., NEW YORK, NY, 10017 Telephone: 269-833-4000 Fax: 616-833-4077 Customer

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/MRL/728/00-FINAL April 2000 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS STREPTOMYCIN AND

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE European Medicines Agency Veterinary Medicines and Inspections EMEA/CVMP/211249/2005-FINAL July 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE DIHYDROSTREPTOMYCIN (Extrapolation to all ruminants)

More information

مادة االدوية المرحلة الثالثة م. غدير حاتم محمد

مادة االدوية المرحلة الثالثة م. غدير حاتم محمد م. مادة االدوية المرحلة الثالثة م. غدير حاتم محمد 2017-2016 ANTIMICROBIAL DRUGS Antimicrobial drugs Lecture 1 Antimicrobial Drugs Chemotherapy: The use of drugs to treat a disease. Antimicrobial drugs:

More information

Chapter Anaerobic infections (individual fields): prevention and treatment of postoperative infections

Chapter Anaerobic infections (individual fields): prevention and treatment of postoperative infections J Infect Chemother (2011) 17 (Suppl 1):62 66 DOI 10.1007/s10156-010-0141-x GUIDELINES Chapter 2-5-1. Anaerobic infections (individual fields): prevention and treatment of postoperative infections Ó Japanese

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Active substance: cefalexin (as cefalexin monohydrate) mg

SUMMARY OF PRODUCT CHARACTERISTICS. Active substance: cefalexin (as cefalexin monohydrate) mg SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cefaseptin 750 mg tablets for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains: Active substance: cefalexin

More information

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.

SUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cephacare flavour 50 mg tablets for cats and dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active

More information

Bacteriology. Mycology. Genova Diagnostics Europe Parkgate House 356 West Barnes Lane New Malden, Surrey. KT3 6NB. Order Number:

Bacteriology. Mycology. Genova Diagnostics Europe Parkgate House 356 West Barnes Lane New Malden, Surrey. KT3 6NB. Order Number: Genova Diagnostics Europe Parkgate House 356 West Barnes Lane New Malden, urrey. KT3 6NB Bacteriology Lactobacillus species 3+ Escherichia coli 4+ Bifidobacterium 3+ gamma haemolytic treptococcus NP 4+

More information

Antimicrobials. Antimicrobials

Antimicrobials. Antimicrobials Antimicrobials For more than 50 years, antibiotics have come to the rescue by routinely producing rapid and long-lasting miracle cures. However, from the beginning antibiotics have selected for resistance

More information

For the treatment of infections caused by a wide range of Gram-positive and Gramnegative pathogenic bacteria including:

For the treatment of infections caused by a wide range of Gram-positive and Gramnegative pathogenic bacteria including: SUMMARY OF PRODUCT CHARCTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amoxycare Suspension for Injection 15% w/v 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains Active Substance(s)

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur...

SUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur... SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT WONDERCEF powder and solvent for solution for injection for horses not intended for the production of foods for human consumption.

More information

Childrens Hospital Antibiogram for 2012 (Based on data from 2011)

Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical

More information

on February 12, 2018 by guest

on February 12, 2018 by guest AAC Accepted Manuscript Posted Online 12 February 2018 Antimicrob. Agents Chemother. doi:10.1128/aac.00047-18 Copyright 2018 Stapert et al. This is an open-access article distributed under the terms of

More information

Burton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents

Burton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/MRL/389/98-FINAL July 1998 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS ENROFLOXACIN (extension to

More information

Other Beta - lactam Antibiotics

Other Beta - lactam Antibiotics Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics

More information

Therios 300 mg and 750 mg Palatable Tablets for Dogs

Therios 300 mg and 750 mg Palatable Tablets for Dogs Ceva Animal Health Ltd Telephone: 01494 781510 Website: www.ceva.com Email: cevauk@ceva.com Therios 300 mg and 750 mg Palatable Tablets for Dogs Species: Therapeutic indication: Active ingredient: Product:

More information

GENERAL NOTES: 2016 site of infection type of organism location of the patient

GENERAL NOTES: 2016 site of infection type of organism location of the patient GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered

More information

Health Products Regulatory Authority

Health Products Regulatory Authority 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Genta 50 mg/ml solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active Substances Gentamicin sulphate equivalent to Gentamicin

More information

Simplicef is Used to Treat Animals with Skin Infections

Simplicef is Used to Treat Animals with Skin Infections Simplicef is Used to Treat Animals with Skin Infections PRODUCT INFO Simplicef tablets are a semi-synthetic cephalosporin antibiotic cefpodoxime proxetil used to cure infections caused by the susceptible

More information

Ecological impact of the des-f(6)-quinolone, BMS , on the normal intestinal microflora C. E. Nord 1, D. A. Gajjar 2 and D. M.

Ecological impact of the des-f(6)-quinolone, BMS , on the normal intestinal microflora C. E. Nord 1, D. A. Gajjar 2 and D. M. ORIGINAL ARTICLE Ecological impact of the des-f(6)-quinolone, BMS-284756, on the normal intestinal microflora C. E. Nord 1, D. A. Gajjar 2 and D. M. Grasela 2 1 Department of Microbiology, Pathology and

More information

Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.

Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Cephalosporins are divided into Generations: -First generation have better activity against gram positive organisms. -Later compounds

More information

Principles of Antimicrobial therapy

Principles of Antimicrobial therapy Principles of Antimicrobial therapy Laith Mohammed Abbas Al-Huseini M.B.Ch.B., M.Sc, M.Res, Ph.D Department of Pharmacology and Therapeutics Antimicrobial agents are chemical substances that can kill or

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Synuclav 250 mg Tablets for Dogs (UK) Clavobay 250 mg Tablets for Dogs (BE, FR, IS, IT, PT) Clavubay 250mg Tablets for Dogs

More information

Cell Wall Inhibitors. Assistant Professor Naza M. Ali. Lec 3 7 Nov 2017

Cell Wall Inhibitors. Assistant Professor Naza M. Ali. Lec 3 7 Nov 2017 Cell Wall Inhibitors Assistant Professor Naza M. Ali Lec 3 7 Nov 2017 Cell wall The cell wall is a rigid outer layer, it completely surrounds the cytoplasmic membrane, maintaining the shape of the cell

More information

Irish Medicines Board

Irish Medicines Board IRISH MEDICINES BOARD ACT 1995, as amended European Communities (Animal Remedies) (No. 2) Regulations 2007 VPA: 10999/033/001A Case No: 7006569 The in exercise of the powers conferred on it by Animal Remedies

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 18 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CLAVUBACTIN 500/125 MG tablets for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances: Amoxicillin

More information

[Version 8.1,01/2017] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

[Version 8.1,01/2017] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS [Version 8.1,01/2017] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Pneumospectin 50 mg/ml +100 mg/ml solution for injection for cattle (calves), sheep, goat, pig,

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metrobactin 500 mg tablets for dogs and cats (AT, BE, BG, CY, CZ, DE, EL, ES, FR, HR, HU, IE, IT, LU, NL, PL, PT, RO, SI,

More information

Active Constituent: Each tablet contains 500 mg cephalexin (as monohydrate) Contents: 12 [100, 300] Tablets

Active Constituent: Each tablet contains 500 mg cephalexin (as monohydrate) Contents: 12 [100, 300] Tablets Carton (main panel) PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY KEFVET 500 mg Tablets for Dogs and Cats Active Constituent: Each tablet contains 500 mg cephalexin

More information

Active Constituent: Each tablet contains 1000 mg cephalexin (as monohydrate) Contents: 8 [100, 300] Tablets

Active Constituent: Each tablet contains 1000 mg cephalexin (as monohydrate) Contents: 8 [100, 300] Tablets Carton (main panel) PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY KEFVET 1000 mg Tablets for Dogs and Cats Active Constituent: Each tablet contains 1000 mg cephalexin

More information

B. PACKAGE LEAFLET 1

B. PACKAGE LEAFLET 1 B. PACKAGE LEAFLET 1 PACKAGE LEAFLET NICILAN 400 mg/100 mg tablets for dogs 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH

More information

Chapter Anaerobic infections (individual fields): intraperitoneal infections (acute peritonitis, hepatobiliary infections, etc.

Chapter Anaerobic infections (individual fields): intraperitoneal infections (acute peritonitis, hepatobiliary infections, etc. J Infect Chemother (2011) 17 (Suppl 1):84 91 DOI 10.1007/s10156-010-0146-5 GUIDELINES Chapter 2-5-4. Anaerobic infections (individual fields): intraperitoneal infections (acute peritonitis, hepatobiliary

More information

OBSTETRICS & GYNAECOLOGY. Penicillin G 5 million units IV ; followed by 2.5 million units 4hourly upto delivery

OBSTETRICS & GYNAECOLOGY. Penicillin G 5 million units IV ; followed by 2.5 million units 4hourly upto delivery OBSTETRICS & GYNAECOLOGY A.OBSTETRICS Infection/Condition/likely organism Intrapartum Group B Streptococcal (GBS) infection; positive mothers Suggested treatment Preferred Penicillin G 5 million units

More information

Antibiotic Prophylaxis Update

Antibiotic Prophylaxis Update Antibiotic Prophylaxis Update Choosing Surgical Antimicrobial Prophylaxis Peri-Procedural Administration Surgical Prophylaxis and AMS at Epworth HealthCare Mr Glenn Valoppi Dr Trisha Peel Dr Joseph Doyle

More information

number Done by Corrected by Doctor

number Done by Corrected by Doctor number 28 Done by Dina Yaseen Corrected by حسام أبو عوض Doctor مالك الزحلف Cephalosporins -Cephalosporins are β-lactam antibiotics isolated from a strain of Streptomyces. -They are bactericidal and work

More information

Approach to pediatric Antibiotics

Approach to pediatric Antibiotics Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus

More information

Author - Dr. Josie Traub-Dargatz

Author - Dr. Josie Traub-Dargatz Author - Dr. Josie Traub-Dargatz Dr. Josie Traub-Dargatz is a professor of equine medicine at Colorado State University (CSU) College of Veterinary Medicine and Biomedical Sciences. She began her veterinary

More information

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory

More information

مادة االدوية المرحلة الثالثة م. غدير حاتم محمد

مادة االدوية المرحلة الثالثة م. غدير حاتم محمد م. مادة االدوية المرحلة الثالثة م. غدير حاتم محمد 2017-2016 ANTIMICROBIAL DRUGS Antimicrobial drugs Lecture 2 The Action of Antimicrobial Drugs 1- Inhibitors of bacterial Cell Wall Synthesis. β-lactams(

More information

SUMMARY OF PRODUCT CHARACTERISTICS 1.B.1 SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS 1.B.1 SUMMARY OF PRODUCT CHARACTERISTICS 1.B. SUMMARY OF PRODUCT CHARACTERISTICS 1.B.1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Lamox 800 mg/g powder for use in drinking water for chickens and pigs 2. QUALITATIVE

More information

Pharmacology Week 6 ANTIMICROBIAL AGENTS

Pharmacology Week 6 ANTIMICROBIAL AGENTS Pharmacology Week 6 ANTIMICROBIAL AGENTS Mechanisms of antimicrobial action Mechanisms of antimicrobial action Bacteriostatic - Slow or stop bacterial growth, needs an immune system to finish off the microbe

More information

GENTAMICIN: ACTIVITY IN VITRO AGAINST GRAMNEGATIVE ORGANISMS AND CLINICAL EXPERIENCES IN THE TREATMENT OF URINARY TRACT INFECTIONS

GENTAMICIN: ACTIVITY IN VITRO AGAINST GRAMNEGATIVE ORGANISMS AND CLINICAL EXPERIENCES IN THE TREATMENT OF URINARY TRACT INFECTIONS 390 CHEMOTHERAPY JULY 1967 GENTAMICIN: ACTIVITY IN VITRO AGAINST GRAMNEGATIVE ORGANISMS AND CLINICAL EXPERIENCES IN THE TREATMENT OF URINARY TRACT INFECTIONS M. OHOKOSHI*, Y. NAIDE, T. KAWAMURA, K. SUZUKI,

More information

MARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS

MARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS MARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL FD 1 %, powder and solvent for solution for injection, for cats and dogs. 2. QUALITATIVE AND QUANTITATIVE

More information

Anaerobic and microaerophilic gram-positive cocci Peptococcus species, Peptostreptococcus species, Microaerophilic streptococci

Anaerobic and microaerophilic gram-positive cocci Peptococcus species, Peptostreptococcus species, Microaerophilic streptococci CLINDACIN Composition Each capsule contains Clindamycin (as hydrochloride) 150 mg Capsule Action Clindamycin bind exclusively to the 50S subunit of bacterial ribosomes and suppress protein synthesis. Clindamycin

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: CP.HNMC.04 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy for important

More information

2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose 2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrocare 50 mg/ml Solution for Injection for Cattle, Pigs, Dogs and Cats (UK, IE, FR) Floxadil 50 mg/ml Solution for Injection

More information

IN VITRO COMBINATION EFFECTS OF NORFLOXACIN, GENTAMICIN, AND Ĉ- LACTAMS ON Ĉ- LACTAM RESISTANT PSEUDOMONAS AERUGINOSA

IN VITRO COMBINATION EFFECTS OF NORFLOXACIN, GENTAMICIN, AND Ĉ- LACTAMS ON Ĉ- LACTAM RESISTANT PSEUDOMONAS AERUGINOSA IN VITRO COMBINATION EFFECTS OF NORFLOXACIN, GENTAMICIN, AND Ĉ- LACTAMS ON Ĉ- LACTAM RESISTANT PSEUDOMONAS AERUGINOSA YONGYUTH JITTAROPAS NAOTO 1), RIKITOMI 2), and Kaizo MATSUMOTO 2) 1) Department of

More information

Approved by the Food Safety Commission on September 30, 2004

Approved by the Food Safety Commission on September 30, 2004 Approved by the Food Safety Commission on September 30, 2004 Assessment guideline for the Effect of Food on Human Health Regarding Antimicrobial- Resistant Bacteria Selected by Antimicrobial Use in Food

More information

Effects of Minocycline and Other Antibiotics on Fusobacterium necrophorum Infections in Mice

Effects of Minocycline and Other Antibiotics on Fusobacterium necrophorum Infections in Mice ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1975, p. 421-425 Copyright 0 1975 American Society for Microbiology Vol. 7, No. 4 Printed in U.S.A. Effects of Minocycline and Other s on Fusobacterium necrophorum

More information

Ofloxacin and the gastrointestinal tract: a potential role in the treatment of bacterial enteritis

Ofloxacin and the gastrointestinal tract: a potential role in the treatment of bacterial enteritis Journal of Antimicrobial Chemotherapy (1990) 26, Suppl D, 45-53 Ofloxacin and the gastrointestinal tract: a potential role in the treatment of bacterial enteritis R. Lang, M. Lbhner, S. Segev and E. Rubinstein

More information

number Done by Corrected by Doctor Dr.Malik

number Done by Corrected by Doctor Dr.Malik number 27 Done by Fatimah Farhan Corrected by Basil Al-Bakri Doctor Dr.Malik Note: anything in red is just extra info and you will not be asked about it in the exam. In this sheet we will continue talking

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Linco-Sol 400 mg/g powder for use in drinking water for pigs and chickens 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active

More information

In Vitro Antimicrobial Activity of CP-99,219, a Novel Azabicyclo-Naphthyridone

In Vitro Antimicrobial Activity of CP-99,219, a Novel Azabicyclo-Naphthyridone ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 39-353 0066-0/93/0039-05$0.00/0 Copyright 993, American Society for Microbiology Vol. 37, No. In Vitro Antimicrobial Activity of, a Novel Azabicyclo-Naphthyridone

More information

PFIZER ANIMAL HEALTH Product Name: LINCO-SPECTIN"" ANTIBIOTIC INJECTABLE SOLUTION Date: 1 November 2011 Page 1 of 9

PFIZER ANIMAL HEALTH Product Name: LINCO-SPECTIN ANTIBIOTIC INJECTABLE SOLUTION Date: 1 November 2011 Page 1 of 9 Date: 1 November 2011 Page 1 of 9 Injectable Solution - Nov 11 (highlighted).doc IMMEDIATE CONTAINER- Main Panel PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY Linco-Spectin

More information

Effect of dalbavancin on the normal intestinal microflora

Effect of dalbavancin on the normal intestinal microflora Journal of Antimicrobial Chemotherapy (00), 1 doi:10.109/jac/dkl1 Advance Access publication 1 July 00 Effect of dalbavancin on the normal intestinal microflora Carl Erik Nord*, Gundars Rasmanis and Elisabeth

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT DOXYPRIM 40% soluble powder 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Doxycycline hyclate 400.0 mg Excipients:

More information

Comparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria

Comparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria Comparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria Juhee Ahn Department of Medical Biomaterials Engineering Kangwon National University October 23, 27 Antibiotic Development

More information

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

1. NAME OF THE VETERINARY MEDICINAL PRODUCT Summary of Prodcuct Characteristics 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrox Max 100 mg/ml Solution for Injection for Cattle and Pigs Enroxal Max 100 mg/ml Solution for Injection for Cattle and

More information

Antibiotics. Antimicrobial Drugs. Alexander Fleming 10/18/2017

Antibiotics. Antimicrobial Drugs. Alexander Fleming 10/18/2017 Antibiotics Antimicrobial Drugs Chapter 20 BIO 220 Antibiotics are compounds produced by fungi or bacteria that inhibit or kill competing microbial species Antimicrobial drugs must display selective toxicity,

More information

VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559. ANTIBIOTIC 6640.* Ill

VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559. ANTIBIOTIC 6640.* Ill VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559 ANTIBIOTIC 6640.* Ill BIOLOGICAL STUDIES WITH ANTIBIOTIC 6640, A NEW BROAD-SPECTRUM AMINOGLYCOSIDE ANTIBIOTIC J. Allan Waitz, Eugene L. Moss, Jr., Edwin

More information

SUMMARY OF PRODUCT CHARACTERISTICS. CEFOKEL 50 mg/ml, suspension for injection for pigs and cattle

SUMMARY OF PRODUCT CHARACTERISTICS. CEFOKEL 50 mg/ml, suspension for injection for pigs and cattle SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CEFOKEL 50 mg/ml, suspension for injection for pigs and cattle 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml of suspension

More information

Fig. 1. Bactericidal effect of guinea-pig complement against E. coil NIHJ JC-2, P. aeruginosa 18 S and S. aureus 209 P

Fig. 1. Bactericidal effect of guinea-pig complement against E. coil NIHJ JC-2, P. aeruginosa 18 S and S. aureus 209 P Fig. 1. Bactericidal effect of guinea-pig complement against E. coil NIHJ JC-2, P. aeruginosa 18 S and S. aureus 209 P Table 1. IDsos of the test antibiotics against each strain of bacterium Fig. 2. Synergy

More information

Selective toxicity. Antimicrobial Drugs. Alexander Fleming 10/17/2016

Selective toxicity. Antimicrobial Drugs. Alexander Fleming 10/17/2016 Selective toxicity Antimicrobial Drugs Chapter 20 BIO 220 Drugs must work inside the host and harm the infective pathogens, but not the host Antibiotics are compounds produced by fungi or bacteria that

More information

Intrinsic, implied and default resistance

Intrinsic, implied and default resistance Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been

More information

MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS

MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL 10%, solution for injection for cattle and swine 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Marbofloxacin...100.0

More information

European Public MRL assessment report (EPMAR)

European Public MRL assessment report (EPMAR) 18 March 2016 EMA/CVMP/619817/2015 Committee for Medicinal Products for Veterinary Use European Public MRL assessment report (EPMAR) Gentamicin (all mammalian food producing species and fin fish) On 3

More information

Protein Synthesis Inhibitors

Protein Synthesis Inhibitors Protein Synthesis Inhibitors Assistant Professor Dr. Naza M. Ali 11 Nov 2018 Lec 7 Aminoglycosides Are structurally related two amino sugars attached by glycosidic linkages. They are bactericidal Inhibitors

More information

International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access.

International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access. I J A P B International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access. ISSN: 2454-8375 COMPARISON OF ANTIMICROBIAL ACTIVITY AND MIC OF BRANDED

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rycarfa 100 mg tablets for dogs (BE, DE, ES, FR, IE, IT, NL, PT, UK) Rycarfa vet 100 mg tablets for dogs (DK, FI) Carprox

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Enrotron 50 mg/ml Solution for injection for cattle, pigs, dogs and cats

SUMMARY OF PRODUCT CHARACTERISTICS. Enrotron 50 mg/ml Solution for injection for cattle, pigs, dogs and cats SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrotron 50 mg/ml Solution for injection for cattle, pigs, dogs and cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each

More information

Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani

Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:

More information

levofloxacin (LVFX) LVFX LVFX LVFX Key words: Levofloxacin Escherichia coli LVFX levofloxacin (LVFX) Vol. 18 No

levofloxacin (LVFX) LVFX LVFX LVFX Key words: Levofloxacin Escherichia coli LVFX levofloxacin (LVFX) Vol. 18 No 2008 221 20 3 14 20 8 1 2001 1 2005 12 5 levofloxacin (LVFX) 5 811 125 27 LVFX (MIC: 4 mg/ml) LVFX LVFX Key words: Levofloxacin Escherichia coli 1) 2 5) 6) ( 203 0036) 2 1 2 TEL: 042 338 5111 2254 FAX:

More information

Antimicrobial Drug on Drug Resistance in the Lactose-Fermenting Enteric Flora

Antimicrobial Drug on Drug Resistance in the Lactose-Fermenting Enteric Flora ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 1975, p. 661-665 Copyright O 1975 American Society for Microbiology Vol. 7, No. 5 Printed in U.S.A. Animal Model for Determining the No-Effect Level of an Antimicrobial

More information

ANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin

ANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria

More information

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016 Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate

More information

Is Clostridium difficile infection influenced by antimicrobial use density in wards?

Is Clostridium difficile infection influenced by antimicrobial use density in wards? Apr. 2013 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 87 29 Is Clostridium difficile infection influenced by antimicrobial use density in wards? NOBUMICHI OGAMI, JUNICHI YOSHIDA, TOSHIYUKI ISHIMARU, TETSUYA

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbocare 20 mg/ml solution for injection for cattle and pigs (UK, IE, FR) Odimar 20 mg/ml solution for injection for cattle

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT ENROXIL 100 mg/ml solution for injection for cattle and pigs (AT, IE, NL, UK) ENROXAL 100 mg/ml solution for injection for

More information

2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services

2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services 2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens

More information

General Approach to Infectious Diseases

General Approach to Infectious Diseases General Approach to Infectious Diseases 2 The pharmacotherapy of infectious diseases is unique. To treat most diseases with drugs, we give drugs that have some desired pharmacologic action at some receptor

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Cemay 50 mg/ml suspension for injection for pigs and cattle 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains: Active

More information

Reduce the risk of recurrence Clear bacterial infections fast and thoroughly

Reduce the risk of recurrence Clear bacterial infections fast and thoroughly Reduce the risk of recurrence Clear bacterial infections fast and thoroughly Clearly advanced 140916_Print-Detailer_Englisch_V2_BAH-05-01-14-003_RZ.indd 1 23.09.14 16:59 In bacterial infections, bacteriological

More information

Chapter 12. Antimicrobial Therapy. Antibiotics 3/31/2010. Spectrum of antibiotics and targets

Chapter 12. Antimicrobial Therapy. Antibiotics 3/31/2010. Spectrum of antibiotics and targets Chapter 12 Topics: - Antimicrobial Therapy - Selective Toxicity - Survey of Antimicrobial Drug - Microbial Drug Resistance - Drug and Host Interaction Antimicrobial Therapy Ehrlich (1900 s) compound 606

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: CP.HNMC.24 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy for important

More information

** the doctor start the lecture with revising some information from the last one:

** the doctor start the lecture with revising some information from the last one: Page 1 of 7 ** the doctor start the lecture with revising some information from the last one: #penicillin G has a good susceptibility against gram(+ve), Neisseria (-ve) #mostly active against strep. (don

More information

DANMAP Danish Integrated Antimicrobial Resistance Monitoring and Research Programme

DANMAP Danish Integrated Antimicrobial Resistance Monitoring and Research Programme DANMAP Danish Integrated Antimicrobial Resistance Monitoring and Research Programme Hanne-Dorthe Emborg Department of Microbiology and Risk Assessment National Food Institute, DTU Introduction The DANMAP

More information

Introduction to Chemotherapeutic Agents. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018

Introduction to Chemotherapeutic Agents. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018 Introduction to Chemotherapeutic Agents Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018 Antimicrobial Agents Substances that kill bacteria without harming the host.

More information

9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS

9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS 1 2 Untoward Effects of Antibiotics Antibiotic resistance Adverse drug events (ADEs) Hypersensitivity/allergy Drug side effects

More information

Sales survey of veterinary medicinal products containing antimicrobials in France in Annual report

Sales survey of veterinary medicinal products containing antimicrobials in France in Annual report Sales survey of veterinary medicinal products containing antimicrobials in France in 2016 Annual report October 2017 Scientific edition Sales survey of veterinary medicinal products containing antimicrobials

More information

Original Article. Ratri Hortiwakul, M.Sc.*, Pantip Chayakul, M.D.*, Natnicha Ingviya, B.Sc.**

Original Article. Ratri Hortiwakul, M.Sc.*, Pantip Chayakul, M.D.*, Natnicha Ingviya, B.Sc.** Original Article In Vitro Activity of Cefminox and Other β-lactam Antibiotics Against Clinical Isolates of Extended- Spectrum-β-lactamase-Producing Klebsiella pneumoniae and Escherichia coli Ratri Hortiwakul,

More information